JP2009507918A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009507918A5 JP2009507918A5 JP2008531200A JP2008531200A JP2009507918A5 JP 2009507918 A5 JP2009507918 A5 JP 2009507918A5 JP 2008531200 A JP2008531200 A JP 2008531200A JP 2008531200 A JP2008531200 A JP 2008531200A JP 2009507918 A5 JP2009507918 A5 JP 2009507918A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- gene product
- cancer
- agent
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001239 microRNA Polymers 0.000 claims 43
- 239000003795 chemical substances by application Substances 0.000 claims 41
- 201000011510 cancer Diseases 0.000 claims 36
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 22
- 102100013894 BCL2 Human genes 0.000 claims 18
- 108060000885 BCL2 Proteins 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 17
- 230000000295 complement Effects 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 11
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 9
- 201000005202 lung cancer Diseases 0.000 claims 9
- 206010025323 Lymphomas Diseases 0.000 claims 8
- 229920002832 Mir-205 Polymers 0.000 claims 8
- 206010025310 Other lymphomas Diseases 0.000 claims 8
- 230000001965 increased Effects 0.000 claims 8
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 7
- 229920001892 Mir-137 Polymers 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229920001899 Mir-143 Polymers 0.000 claims 5
- 229920001650 Mir-96 microRNA Polymers 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 5
- 230000001093 anti-cancer Effects 0.000 claims 5
- 229940079593 drugs Drugs 0.000 claims 5
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 201000006845 reticulosarcoma Diseases 0.000 claims 4
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 201000005244 lung non-small cell carcinoma Diseases 0.000 claims 3
- 230000002018 overexpression Effects 0.000 claims 3
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 2
- 210000004556 Brain Anatomy 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 2
- 206010061232 Lymphoproliferative disease Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 201000009030 carcinoma Diseases 0.000 claims 2
- 201000011231 colorectal cancer Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000009251 multiple myeloma Diseases 0.000 claims 2
- 201000001514 prostate carcinoma Diseases 0.000 claims 2
- 201000010174 renal carcinoma Diseases 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 201000000498 stomach carcinoma Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 206010059512 Apoptosis Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000003183 carcinogenic agent Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001472 cytotoxic Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
Claims (73)
- BCL2遺伝子転写体中のヌクレオチド配列と相補的であるヌクレオチド配列を含んでなる少なくとも一つのmiR遺伝子産物を有効成分として含む、BCL2関連癌の抗癌治療の効力を増加させるための薬剤。
- 少なくとも一つのmiR遺伝子産物がmiR−15a又はmiR−16−1である、請求項1に記載の薬剤。
- 少なくとも一つのmiR遺伝子産物が、miR−182、miR−181、miR−30、miR−15a、miR−16−1、miR−15b、miR−16−2、miR−195、miR−34、miR−153、miR−21、miR−217、miR−205、miR−204、miR−211、miR−143、miR−96、miR−103、miR−107、miR−129、miR−9、miR−137、miR−217、miR−186及びそれらの組み合わせから成る群より選択される、請求項1に記載の薬剤。
- 少なくとも一つのmiR遺伝子産物が、miR−182、miR−181、miR−30、miR−15a、miR−16−1、miR−15b、miR−16−2、miR−195及びそれらの組み合わせから成る群より選択される、請求項1に記載の薬剤。
- 少なくとも一つのmiR遺伝子産物が、配列番号55のヌクレオチド3741〜3749と相補的であるヌクレオチド配列を含んでなる、請求項1に記載の薬剤。
- 抗癌治療が化学療法である、請求項1に記載の薬剤。
- 抗癌治療が放射線療法である、請求項1に記載の薬剤。
- 癌が慢性リンパ球性白血病(CLL)である、請求項1に記載の薬剤。
- 癌がリンパ腫である、請求項1に記載の薬剤。
- リンパ腫が濾胞性リンパ腫、小細胞リンパ腫、大細胞リンパ腫及び非ホジキンリンパ腫から成る群より選択される、請求項9に記載の薬剤。
- 癌が肺癌である、請求項1に記載の薬剤。
- 抗癌治療の効力の増加が、適した対照と比較して、対象における癌の増加した寛解によって証明される、請求項1に記載の薬剤。
- BCL2関連癌を有するヒトにおいて抗癌治療の効力を増加させるために使用される、請求項1に記載の薬剤。
- BCL2遺伝子転写体中のヌクレオチド配列と相補的であるヌクレオチド配列を含んでなる少なくとも一つのmiR遺伝子産物を有効成分として含む、抗癌剤の細胞傷害性効果に対する癌細胞の感受性を増加させるための薬剤。
- 少なくとも一つのmiR遺伝子産物が、miR−15a又はmiR−16−1である、請求項14に記載の薬剤。
- 少なくとも一つのmiR遺伝子産物が、miR−182、miR−181、miR−30、miR−15a、miR−16−1、miR−15b、miR−16−2、miR−195、miR−34、miR−153、miR−21、miR−217、miR−205、miR−204、miR−211、miR−143、miR−96、miR−103、miR−107、miR−129、miR−9、miR−137、miR−217、miR−186及びそれらの組み合わせから成る群より選択される、請求項14に記載の薬剤。
- 少なくとも一つのmiR遺伝子産物が、miR−182、miR−181、miR−30、miR−15a、miR−16−1、miR−15b、miR−16−2、miR−195及びそれらの組み合わせから成る群より選択される、請求項14に記載の薬剤。
- 少なくとも一つのmiR遺伝子産物が、配列番号55のヌクレオチド3741〜3749と相補的であるヌクレオチド配列を含んでなる、請求項14に記載の薬剤。
- 癌細胞が、対照細胞と比較してBcl2タンパク質の増加した発現を示す、請求項14に記載の薬剤。
- 癌細胞が対象中に存在する、請求項14に記載の薬剤。
- 対象がヒトである、請求項20に記載の薬剤。
- 癌細胞がCLL細胞、肺癌細胞及びリンパ腫細胞から成る群より選択される、請求項14に記載の薬剤。
- 癌細胞が濾胞性リンパ腫細胞、小細胞リンパ腫細胞、大細胞リンパ腫細胞及び非ホジキンリンパ腫細胞から成る群より選択されるリンパ腫細胞である、請求項22に記載の薬剤。
- 癌細胞が肺癌細胞である、請求項14に記載の薬剤。
- 肺癌が非小細胞肺癌腫細胞である、請求項24に記載の薬剤。
- 癌細胞が、急性骨髄性白血病、多発性骨髄腫、メラノーマ、血液悪性腫瘍、固形腫瘍、結腸直腸癌、脳癌腫、乳癌腫、前立腺癌腫、エプスタイン・バーウイルス関連リンパ球増殖性疾患、腎癌腫、肝細胞癌腫及び胃癌腫から成る群より選択される癌と関連している細胞である、請求項14に記載の薬剤。
- 抗癌剤に対する癌細胞の感受性の増加が、該癌細胞の死により証明される、請求項14に記載の薬剤。
- 少なくとも一つのmiR遺伝子産物がBCL2遺伝子転写体中のヌクレオチド配列と相補的であるヌクレオチド配列を含んでなる少なくとも一つのmiR遺伝子産物を有効成分として含む、細胞にアポトーシスを誘発する薬剤。
- 少なくとも一つのmiR遺伝子産物が、miR−15a又はmiR−16−1である、請求項28に記載の薬剤。
- 少なくとも一つのmiR遺伝子産物が、miR−182、miR−181、miR−30、miR−15a、miR−16−1、miR−15b、miR−16−2、miR−195、miR−34、miR−153、miR−21、miR−217、miR−205、miR−204、miR−211、miR−143、miR−96、miR−103、miR−107、miR−129、miR−9、miR−l37、miR−217、miR−186及びそれらの組み合わせから成る群より選択される、請求項28に記載の薬剤。
- 少なくとも一つのmiR遺伝子産物が、miR−182、miR−181、miR−30、miR−15a、miR−16−1、miR−15b、miR−16−2、miR−195及びそれらの組み合わせから成る群より選択される、請求項28に記載の薬剤。
- 少なくとも一つのmiR遺伝子産物が、配列番号55のヌクレオチド3741〜3749と相補的であるヌクレオチド配列を含んでなる、請求項28に記載の薬剤。
- 細胞が癌細胞である、請求項28に記載の薬剤。
- 癌細胞が、対照細胞と比較してBcl2タンパク質の増加した発現を示す、請求項33に記載の薬剤。
- 癌細胞がCLL細胞、肺癌細胞及びリンパ腫細胞から成る群より選択される、請求項33に記載の薬剤。
- 癌細胞が濾胞性リンパ腫細胞、小細胞リンパ腫細胞、大細胞リンパ腫細胞及び非ホジキンリンパ腫細胞から成る群より選択されるリンパ腫細胞である、請求項35に記載の薬剤。
- 癌細胞が肺癌細胞である、請求項35に記載の薬剤。
- 肺癌が非小細胞肺癌腫細胞である、請求項37に記載の薬剤。
- 癌細胞が、急性骨髄性白血病、多発性骨髄腫、メラノーマ、血液悪性腫瘍、固形腫瘍、結腸直腸癌、脳癌腫、乳癌腫、前立腺癌腫、エプスタイン・バーウイルス関連リンパ球増殖性疾患、腎癌腫、肝細胞癌腫及び胃癌腫から成る群より選択される癌と関連している細胞である、請求項33に記載の薬剤。
- 癌細胞が対象中に存在する、請求項28に記載の薬剤。
- 対象がヒトである、請求項40に記載の薬剤。
- 少なくとも一つのmiR遺伝子産物はBCL2遺伝子転写体中のヌクレオチド配列と相補的であるヌクレオチド配列を含んでなる少なくとも一つのmiR遺伝子産物を有効成分とする、対象中のBCL2遺伝子産物の過剰発現に関連する癌の治療剤。
- 少なくとも一つのmiR遺伝子産物が、miR−15b又はmiR−16−2である、請求項42に記載の治療剤。
- 少なくとも一つのmiR遺伝子産物が、miR−181b、miR−181c、miR−181d、miR−30、miR−15b、miR−16−2、miR−153−1、miR−217、miR−205、miR−204、miR−103、miR−107、miR−129−2、miR−9、miR−137及びそれらの組み合わせから成る群より選択される、請求項42に記載の治療剤。
- 少なくとも一つのmiR遺伝子産物が、配列番号55のヌクレオチド3741〜3749と相補的であるヌクレオチド配列を含んでなる、請求項42に記載の治療剤。
- 対象がヒトである、請求項42に記載の治療剤。
- 癌が慢性リンパ球性白血病(CLL)である、請求項42に記載の治療剤。
- 癌がリンパ腫である、請求項42に記載の治療剤。
- リンパ腫が、濾胞性リンパ腫、大細胞リンパ腫及び非ホジキンリンパ腫から成る群より選択される、請求項48に記載の治療剤。
- 癌が肺癌である、請求項42に記載の治療剤。
- 肺癌が非小細胞肺癌腫である、請求項50に記載の治療剤。
- miR遺伝子産物はmiR−15a又はmiR−16−1ではない、請求項42ないし51の何れか1項に記載の治療剤。
- 少なくとも一つのmiR遺伝子産物が、miR−30、miR−15b、miR−16−2、miR−217、miR−205、miR−204、miR−103、miR−107、miR−9及びmiR−137から成る群より選択される、請求項42に記載の治療剤。
- Bcl2関連癌を治療するための医薬組成物であって、少なくとも一つの抗癌剤及び少なくとも一つのmiR遺伝子産物を含んでなり、該少なくとも一つのmiR遺伝子産物が、BCL2遺伝子転写体中のヌクレオチド配列と相補的であるヌクレオチド配列を含んでなる、前記医薬組成物。
- 少なくとも一つのmiR遺伝子産物が、配列番号55のヌクレオチド3741〜3749と相補的であるヌクレオチド配列を含んでなる、請求項54に記載の医薬組成物。
- 少なくとも一つのmiR遺伝子産物がmiR−15aである、請求項54に記載の医薬組成物。
- 少なくとも一つのmiR遺伝子産物がmiR−16−1である、請求項54に記載の医薬組成物。
- 少なくとも一つのmiR遺伝子産物が、miR−182、miR−181、miR−30、miR−15a、miR−16−1、miR−15b、miR−16−2、miR−195、miR−34、miR−153、miR−21、miR−217、miR−205、miR−204、miR−211、miR−143、miR−96、miR−103、miR−107、miR−129、miR−9、miR−137、miR−217、miR−186及びそれらの組み合わせから成る群より選択される、請求項54に記載の医薬組成物。
- BCL2遺伝子転写体中のヌクレオチド配列と相補的であるヌクレオチド配列を含んでなる少なくとも一つの療法剤を投与された対象からのサンプル中の少なくとも一つのmiR遺伝子産物の発現を測定することを含む、対象中の癌療法の効力を決定するための方法。
- 対象がCLLを有する、請求項59に記載の方法。
- 対象がBcl2タンパク質の過剰発現に関連した癌を有する、請求項59に記載の方法。
- miR遺伝子産物が、miR−15a、miR−16−1、miR−15b、miR−16−2又はそれらの組み合わせである、請求項59に記載の方法。
- 適した対照と比較したmiRの遺伝子産物の発現の増加が、成功した治療を示す、請求項59に記載の方法。
- BCL2遺伝子転写体中のヌクレオチド配列と相補的であるヌクレオチド配列を含んでなる少なくとも一つのmiR遺伝子産物を有効成分として含む、BCL2遺伝子産物の過剰発現に関連した癌を予防する薬剤。
- miR遺伝子産物はmiR−15a又はmiR−16−1ではない、請求項64に記載の方法。
- 少なくとも一つのmiR遺伝子産物が、miR−30、miR−15b、miR−16−2、miR−217、miR−205、miR−204、miR−103、miR−107、miR−9及びmiR−137から成る群より選択される、請求項64または65に記載の方法。
- 少なくとも一つのmiR遺伝子中の欠失又は変異を検出する方法であって:
i)BCL2関連癌を有する疑いのある対象からのサンプル中の遺伝子の構造又は配列を決定すること;及び
ii)上記遺伝子の構造又は配列を、該対象からの冒されていない組織のサンプル中又は正常対照からの組織のサンプル中の、これらの遺伝子の構造又は配列と比較するが、ここで対照からのものと比較して、対象からのサンプル中の少なくとも一つのmiR遺伝子産物のレベルにおける減少が、BCL2関連癌の診断又は予後診断であり、そして、
少なくとも一つのmiR遺伝子産物は、BCL2遺伝子転写体中のヌクレオチド配列と相補的であるヌクレオチド配列を含んでなること;
を含んでなる、前記方法。 - 少なくとも一つのmiR遺伝子産物が、miR−15a又はmiR−16−1である、請求項67に記載の方法。
- 少なくとも一つのmiR遺伝子産物が、miR−182、miR−181、miR−30、miR−15a、miR−16−1、miR−15b、miR−16−2、miR−195、miR−34、miR−153、miR−21、miR−217、miR−205、miR−204、miR−211、miR−143、miR−96、miR−103、miR−107、miR−129、miR−9、miR−137、miR−217、miR−186及びそれらの組み合わせから成る群より選択される、請求項67に記載の方法。
- 少なくとも一つのmiR遺伝子産物が、miR−182、miR−181、miR−30、miR−15a、miR−16−1、miR−15b、miR−16−2、miR−195及びそれらの組み合わせから成る群より選択される、請求項67に記載の方法。
- 少なくとも一つのmiR遺伝子産物が、配列番号55のヌクレオチド3741〜3749と相補的であるヌクレオチド配列を含んでなる、請求項67に記載の方法。
- 対照が、BCL2関連癌を有していない対象からの少なくとも一つのmiR遺伝子産物のレベルである、請求項67に記載の方法。
- 対照が、対象の非癌性サンプルからの少なくとも一つのmiR遺伝子産物のレベルである、請求項67に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71613405P | 2005-09-12 | 2005-09-12 | |
PCT/US2006/035100 WO2007033023A2 (en) | 2005-09-12 | 2006-09-11 | Compositions and methods for the diagnosis and therapy of bcl2-associated cancers |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013081761A Division JP2013166766A (ja) | 2005-09-12 | 2013-04-10 | Bcl2関連癌の診断及び療法のための組成物及び方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009507918A JP2009507918A (ja) | 2009-02-26 |
JP2009507918A5 true JP2009507918A5 (ja) | 2009-11-05 |
Family
ID=37865464
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008531200A Pending JP2009507918A (ja) | 2005-09-12 | 2006-09-11 | Bcl2関連癌の診断及び療法のための組成物及び方法 |
JP2013081761A Pending JP2013166766A (ja) | 2005-09-12 | 2013-04-10 | Bcl2関連癌の診断及び療法のための組成物及び方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013081761A Pending JP2013166766A (ja) | 2005-09-12 | 2013-04-10 | Bcl2関連癌の診断及び療法のための組成物及び方法 |
Country Status (8)
Country | Link |
---|---|
US (3) | US8481505B2 (ja) |
EP (2) | EP1937280B1 (ja) |
JP (2) | JP2009507918A (ja) |
CN (2) | CN101296702B (ja) |
AU (1) | AU2006291165B2 (ja) |
CA (2) | CA2621441C (ja) |
ES (1) | ES2523989T3 (ja) |
WO (1) | WO2007033023A2 (ja) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2471922A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, Inc. | Methods and compositions involving microRNA |
US8173611B2 (en) | 2004-11-12 | 2012-05-08 | Asuragen Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US8592384B2 (en) | 2005-04-04 | 2013-11-26 | The Board Of Regents Of The University Of Texas System | Micro-RNA's that regulate muscle cells |
CA2617581A1 (en) | 2005-08-01 | 2007-02-08 | The Ohio State University Research Foundation | Microrna-based methods for the diagnosis of breast cancer |
EP1937280B1 (en) | 2005-09-12 | 2014-08-27 | The Ohio State University Research Foundation | Compositions for the therapy of bcl2-associated cancers |
CA2624531A1 (en) * | 2005-10-05 | 2007-04-19 | Carlo M. Croce | Wwox gene, vectors containing the same, and uses in treatment of cancer |
CN102943108B (zh) | 2006-01-05 | 2014-05-21 | 俄亥俄州立大学研究基金会 | 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物 |
AU2007205257B2 (en) | 2006-01-05 | 2013-07-25 | The Ohio State University Research Foundation | MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors |
EP2468899B1 (en) | 2006-01-05 | 2015-03-11 | The Ohio State University Research Foundation | MicroRNA-based methods for the diagnosis of stomach cancers |
AU2007227423B2 (en) | 2006-03-20 | 2013-11-07 | The Ohio State University Research Foundation | MicroRNA fingerprints during human megakaryocytopoiesis |
EP2369017B8 (en) | 2006-07-13 | 2014-03-12 | The Ohio State University Research Foundation | Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases |
CN101535505A (zh) | 2006-09-19 | 2009-09-16 | 俄亥俄州立大学研究基金会 | 慢性淋巴细胞性白血病(CLL)中受miR-29和miR-181调控的TCL1的表达 |
WO2008054828A2 (en) | 2006-11-01 | 2008-05-08 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
AU2007333110A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miRNA regulated genes and pathways as targets for therapeutic intervention |
CN103555825B (zh) | 2007-01-31 | 2015-09-30 | 俄亥俄州立大学研究基金会 | 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物 |
JP2010529966A (ja) * | 2007-06-08 | 2010-09-02 | アシュラジェン インコーポレイテッド | 治療的介入の標的としてmiR−34によって調節される遺伝子および経路 |
ES2537349T3 (es) | 2007-06-08 | 2015-06-05 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Métodos para determinar un subtipo de carcinoma hepatocelular |
EP2719773A3 (en) * | 2007-06-15 | 2014-07-30 | The Ohio State University Research Foundation | miRNA as marker for acute lamphomic leucemia |
JP5587777B2 (ja) | 2007-07-31 | 2014-09-10 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 線維症をモジュレートするマイクロrnaファミリー及びその使用 |
WO2009018303A2 (en) | 2007-07-31 | 2009-02-05 | The Ohio State University Research Foundation | Methods for reverting methylation by targeting dnmt3a and dnmt3b |
CN103866008B (zh) * | 2007-08-03 | 2016-06-29 | 俄亥俄州立大学研究基金会 | 编码ncrna的超保守区域 |
CA2696887C (en) | 2007-08-22 | 2016-06-28 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
US8361714B2 (en) | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
AU2008316577B2 (en) | 2007-10-26 | 2014-04-10 | The Ohio State University Research Foundation | Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof |
BRPI0818901A2 (pt) | 2007-11-09 | 2015-05-12 | Univ Texas | Micro-rnas da família mir-15 modulam sobrevivência de cardiomiócitos e reparo cardíaco |
AU2008329755A1 (en) * | 2007-11-30 | 2009-06-04 | The Ohio State University Research Foundation | MicroRNA expression profiling and targeting in peripheral blood in lung cancer |
US7964354B2 (en) | 2007-12-20 | 2011-06-21 | Celgene Corporation | Use of micro-RNA as a biomarker of immunomodulatory drug activity |
CN104031984A (zh) * | 2008-02-28 | 2014-09-10 | 俄亥俄州立大学研究基金会 | 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物 |
WO2009108856A2 (en) * | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof |
US8202848B2 (en) | 2008-03-17 | 2012-06-19 | Board Of Regents, The University Of Texas System | Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration |
US20090253780A1 (en) * | 2008-03-26 | 2009-10-08 | Fumitaka Takeshita | COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER |
US9261508B2 (en) | 2008-04-25 | 2016-02-16 | Istituto Superiore Di Sanita | Antisense RNA for treating cancer and inhibition of metastasis and vectors for antisense sequestration |
WO2009137807A2 (en) | 2008-05-08 | 2009-11-12 | Asuragen, Inc. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
EP2307028B1 (en) | 2008-06-11 | 2013-10-02 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy |
WO2010036939A2 (en) * | 2008-09-26 | 2010-04-01 | University Of Southern California | A system for synergistic expression of multiple small functional rna elements |
US20110201103A1 (en) * | 2008-08-07 | 2011-08-18 | University Of Southern California | System For Synergetic Expression Of Multiple Small Functional RNA Elements |
WO2010020787A1 (en) * | 2008-08-22 | 2010-02-25 | Oncomethylome Sciences Sa | Diagnosis and treatment of tumours |
ES2610622T3 (es) * | 2009-03-31 | 2017-04-28 | The General Hospital Corporation | Regulación de microARN miR-33 en el tratamiento de trastornos relacionados con colesterol |
CN101988060A (zh) * | 2009-07-30 | 2011-03-23 | 江苏命码生物科技有限公司 | 结直肠癌检测标记物及其检测方法、试剂盒和生物芯片 |
CN102803511A (zh) | 2009-11-23 | 2012-11-28 | 俄亥俄州立大学 | 用于影响肿瘤细胞生长、迁移和侵袭的材料和方法 |
NZ605420A (en) * | 2010-07-06 | 2015-02-27 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
CN103153341B (zh) * | 2010-08-03 | 2015-05-27 | 霍夫曼-拉罗奇有限公司 | 慢性淋巴细胞性白血病(cll)生物标志物 |
WO2012041959A1 (en) | 2010-09-30 | 2012-04-05 | University Of Zurich | Treatment of b-cell lymphoma with microrna |
SG180031A1 (en) * | 2010-10-15 | 2012-05-30 | Agency Science Tech & Res | Combination treatment of cancer |
AU2011326032B2 (en) | 2010-11-12 | 2016-10-06 | The Ohio State University Research Foundation | Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer |
BR112013011942A2 (pt) | 2010-11-15 | 2016-11-01 | Univ Michigan | formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida. |
JP2014509852A (ja) | 2011-03-07 | 2014-04-24 | ジ・オハイオ・ステート・ユニバーシティ | マイクロRNA−155(miR−155)により誘導される変異誘発活性は炎症および癌を結び付ける |
ES2732427T3 (es) | 2011-08-04 | 2019-11-22 | Yeda Res & Dev | Micro-ARN MIR-15 y composiciones que lo comprenden para el tratamiento de enfermedades asociadas con la hormona liberadora de corticotropina |
WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
EP2757154A4 (en) | 2011-09-16 | 2015-10-14 | Lsip Llc | METHOD FOR DETECTING BLOOD TUMOR CELLS, PRIMER FOR USE IN THIS METHOD FOR DETECTING BLOOD TUMOR CELLS AND BLADDER CANCER MARKERS |
AU2012323924A1 (en) | 2011-10-14 | 2014-05-29 | The Ohio State University | Methods and materials related to ovarian cancer |
JP2015501645A (ja) * | 2011-12-10 | 2015-01-19 | オハイオ・ステイト・イノベーション・ファウンデーション | 肺がんの腫瘍発生および化学療法耐性を低減するために有用なmiRNAならびに関連する組成物および方法 |
CN104619353A (zh) | 2011-12-13 | 2015-05-13 | 俄亥俄州国家创新基金会 | 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移 |
CN102559876A (zh) * | 2011-12-19 | 2012-07-11 | 苏州福英基因科技有限公司 | 癌症病理演变前期microrna-16-1水平原位杂交检测试剂盒及检测方法和应用 |
AU2013209477B2 (en) * | 2012-01-20 | 2016-12-08 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
CN103374630B (zh) * | 2012-04-30 | 2014-10-08 | 财团法人工业技术研究院 | 侦测罹患肝癌机率的方法 |
US9163235B2 (en) | 2012-06-21 | 2015-10-20 | MiRagen Therapeutics, Inc. | Inhibitors of the miR-15 family of micro-RNAs |
US9603873B2 (en) * | 2012-12-03 | 2017-03-28 | Ohio State Innovation Foundation | Activation of innate immunity by miRNA for cancer and infection treatment |
CN103343160B (zh) * | 2013-05-03 | 2014-12-10 | 中国人民解放军南京军区南京总医院 | microRNA-30家族的新用途 |
US10697020B2 (en) | 2013-05-15 | 2020-06-30 | The Research Foundation For The State University Of New York | MicroRNA-129 as a biomarker for colorectal cancer |
CN106029887A (zh) * | 2013-12-02 | 2016-10-12 | 格拉斯哥大学理事会 | 用于治疗肺动脉高血压的材料和方法 |
WO2015118537A2 (en) | 2014-02-05 | 2015-08-13 | Yeda Research And Development Co. Ltd. | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
US9518300B2 (en) * | 2014-04-14 | 2016-12-13 | Dana-Farber Cancer Institute, Inc. | Composition and method for treating a hematological malignancy |
CN103911458A (zh) * | 2014-04-28 | 2014-07-09 | 南京医科大学第一附属医院 | 检测MiR-34b/crs4938723突变体的引物及其在制备胃癌筛查试剂盒中的应用 |
CN105039537B (zh) * | 2014-07-10 | 2018-07-06 | 上海益诺思生物技术股份有限公司 | mo-miR-211在制备肾毒性生物标志物中的用途 |
CN105363042B (zh) * | 2015-10-21 | 2022-05-06 | 圣诺生物医药技术(苏州)有限公司 | 一种药物组合物及其应用 |
CN109312341B (zh) | 2016-03-07 | 2024-02-27 | 美国政府(由卫生和人类服务部的部长所代表) | 微小rna及其使用方法 |
CN105755027B (zh) * | 2016-04-08 | 2020-02-04 | 北京大学深圳医院 | 一种基于miRNA137调节DAT基因表达的方法 |
WO2017213851A1 (en) * | 2016-06-09 | 2017-12-14 | The Board Of Regents Of The University Of Texas System | Inhibitory rna-based therapeutics targeting anln for cancer treatment |
CN110290794A (zh) * | 2016-11-01 | 2019-09-27 | 纽约州州立大学研究基金会 | 5-卤代尿嘧啶修饰的微rna及其在癌症治疗中的用途 |
US11419843B2 (en) * | 2016-12-01 | 2022-08-23 | Oregon State University | Small molecule BCL-2 functional converters as cancer therapeutics |
CN110636853A (zh) * | 2017-05-19 | 2019-12-31 | 佐治亚州立大学研究基金会公司 | 重组溶瘤病毒 |
CN111349704B (zh) * | 2020-03-17 | 2020-11-24 | 河北医科大学第三医院 | 肝癌的诊断产品和治疗组合物 |
EP4127175A2 (en) | 2020-04-02 | 2023-02-08 | Mirecule, Inc. | Targeted inhibition using engineered oligonucleotides |
EP4138845A1 (en) * | 2020-04-21 | 2023-03-01 | Carlo M. Croce | Methods of detecting and treating cancers characterized by loss of mir15 and mir16 expression |
CN111850047B (zh) * | 2020-07-28 | 2022-08-12 | 枣庄学院 | 一种miR-16与miR-30c联合表达载体及其构建方法与应用 |
CN112007043B (zh) * | 2020-08-24 | 2021-07-20 | 谢琦 | 抗结直肠癌的药物或组合物 |
CN111920700B (zh) * | 2020-09-17 | 2021-01-29 | 北京达熙生物科技有限公司 | 一种干细胞外泌体的制备技术及在药品和化妆品中的应用 |
CN112516317B (zh) * | 2020-12-10 | 2021-12-17 | 暨南大学附属第一医院(广州华侨医院) | 一种预防和治疗癌症的药物组合物及其应用 |
Family Cites Families (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
US4608337A (en) | 1980-11-07 | 1986-08-26 | The Wistar Institute | Human hybridomas and the production of human monoclonal antibodies by human hybridomas |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4701409A (en) | 1984-11-15 | 1987-10-20 | The Wistar Institute | Detection of B-cell neoplasms |
US4693975A (en) | 1984-11-20 | 1987-09-15 | The Wistar Institute | Human hybridroma fusion partner for production of human monoclonal antibodies |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5015568A (en) * | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
US5202429A (en) * | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
DE68921918T2 (de) | 1988-05-09 | 1995-09-07 | Univ Temple | Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten. |
US5198338A (en) * | 1989-05-31 | 1993-03-30 | Temple University | Molecular probing for human t-cell leukemia and lymphoma |
US5149628A (en) | 1989-11-15 | 1992-09-22 | Temple University | Methods for detecting bcl-3 gene in human leukemias |
US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US5633135A (en) * | 1991-12-11 | 1997-05-27 | Thomas Jefferson University | Chimeric nucleic acids and proteins resulting from ALL-1 region chromosome abnormalities |
US6040140A (en) * | 1991-12-11 | 2000-03-21 | Thomas Jefferson University | Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities |
WO1993012136A1 (en) * | 1991-12-11 | 1993-06-24 | Thomas Jefferson University | Detection and treatment of acute leukemias resulting from chromosome abnormalities in the all-1 region |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
PT667920E (pt) | 1992-10-29 | 2003-06-30 | Univ Jefferson | Metodos de deteccao de micrometasteses do cancro da prostata |
US5674682A (en) | 1992-10-29 | 1997-10-07 | Thomas Jefferson University | Nucleic acid primers for detecting micrometastasis of prostate cancer |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US7175995B1 (en) * | 1994-10-27 | 2007-02-13 | Thomas Jefferson University | TCL-1 protein and related methods |
US5985598A (en) * | 1994-10-27 | 1999-11-16 | Thomas Jefferson University | TCL-1 gene and protein and related methods and compositions |
US5789389A (en) | 1995-03-17 | 1998-08-04 | Board Of Trustees Of University Of Illinois | BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs |
US5695944A (en) | 1995-05-05 | 1997-12-09 | Thomas Jefferson University | Modulation of bcl-2 phosphorylation |
US5567586A (en) | 1995-05-18 | 1996-10-22 | Thomas Jefferson University | Methods of indentifying solid tumors with chromosome abnormalities in the ALL-1 region |
US6242212B1 (en) | 1996-02-09 | 2001-06-05 | Thomas Jefferson University | Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins |
US5928884A (en) * | 1996-02-09 | 1999-07-27 | Croce; Carlo M. | FHIT proteins and nucleic acids and methods based thereon |
US6187536B1 (en) | 1997-02-18 | 2001-02-13 | Thomas Jefferson University | Methods of identifying and detecting pancreatic cancer |
AU6951098A (en) * | 1997-04-04 | 1998-10-30 | The Texas A & M University System | Noninvasive detection of colonic biomarkers using fecal messenger rna |
WO2000003685A2 (en) * | 1998-07-20 | 2000-01-27 | Thomas Jefferson University | Nitrilase homologs |
US6255293B1 (en) * | 1998-07-24 | 2001-07-03 | Yeda Research And Development Co., Ltd. | Prevention of metastasis with 5-aza-2′-deoxycytidine |
US7141417B1 (en) * | 1999-02-25 | 2006-11-28 | Thomas Jefferson University | Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene |
EP1165586A4 (en) | 1999-03-15 | 2003-05-28 | Univ Jefferson | TCL-1B GENES AND PROTEINS AND RELATED METHODS AND METHODS |
US7163801B2 (en) | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
US6891031B2 (en) | 2000-02-18 | 2005-05-10 | The Regents Of The University Of California | Coordinate cytokine regulatory sequences |
WO2001068666A1 (en) | 2000-03-14 | 2001-09-20 | Thomas Jefferson University | Tcl1 enhances akt kinase activity and mediates its nuclear translocation |
AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
JP2004516002A (ja) * | 2000-04-11 | 2004-06-03 | トーマス・ジェファーソン・ユニバーシティー | Fhit欠損マウスにおけるミュア−トール様症候群 |
US20020086331A1 (en) * | 2000-05-16 | 2002-07-04 | Carlo Croce | Crystal structure of worm NitFhit reveals that a Nit tetramer binds two Fhit dimers |
US7060811B2 (en) * | 2000-10-13 | 2006-06-13 | Board Of Regents, The University Of Texas System | WWOX: a tumor suppressor gene mutated in multiple cancers |
DE60234577D1 (de) | 2001-03-23 | 2010-01-14 | Shire Canada Inc | Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält |
US20040033502A1 (en) * | 2001-03-28 | 2004-02-19 | Amanda Williams | Gene expression profiles in esophageal tissue |
US20050176025A1 (en) | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
EP2385123B1 (en) * | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
US7371736B2 (en) * | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
GB0128898D0 (en) * | 2001-12-03 | 2002-01-23 | Biotech Res Ventures Pte Ltd | Materials and methods relating to the stabilization and activation of a tumour suppressor protein |
JP2005517452A (ja) * | 2002-02-20 | 2005-06-16 | サーナ・セラピューティクス・インコーポレイテッド | 短干渉核酸(siNA)を用いるBCL2遺伝子発現のRNA干渉媒介性阻害 |
AU2003224672B2 (en) | 2002-03-08 | 2010-02-04 | Eisai R&D Management Co., Ltd. | Macrocyclic compounds useful as pharmaceuticals |
EP1496928A4 (en) * | 2002-04-08 | 2005-08-10 | Ciphergen Biosystems Inc | SERUM BIOMARKERS IN HEPATOCELLULAR CARCINOMA |
ATE446675T1 (de) * | 2002-04-29 | 2009-11-15 | Univ Jefferson | Humane chronische lymphozytische leukämie im mausmodell durch gezielte expression von tcl1 |
US7217568B2 (en) * | 2002-05-31 | 2007-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of identifying and isolating stem cells and cancer stem cells |
US20050260639A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
US20050266443A1 (en) | 2002-10-11 | 2005-12-01 | Thomas Jefferson University | Novel tumor suppressor gene and compositions and methods for making and using the same |
AU2003284083A1 (en) * | 2002-10-11 | 2004-05-04 | Thomas Jefferson University | Novel tumor suppressor gene and compositions and methods for making and using the same |
WO2004043387A2 (en) | 2002-11-13 | 2004-05-27 | Thomas Jefferson University | Compositions and methods for cancer diagnosis and therapy |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
WO2004071464A2 (en) * | 2003-02-12 | 2004-08-26 | Johns Hopkins University School Of Medicine | Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells |
US7183384B2 (en) | 2003-03-06 | 2007-02-27 | A & G Pharmaceutical, Inc. | Monoclonal antibody 7H11 reactive with human cancer |
WO2006031210A1 (en) * | 2003-05-29 | 2006-03-23 | Board Of Regents, The University Of Texas Systems | Jabi as a prognostic marker and a therapeutic target for human cancer |
DE602004018927D1 (de) | 2003-06-18 | 2009-02-26 | Genelux Corp | Modifizierte rekombinante vacciniaviren, verwendungen davon |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
WO2005047505A2 (en) * | 2003-08-07 | 2005-05-26 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro rnas |
US20050037362A1 (en) * | 2003-08-11 | 2005-02-17 | Eppendorf Array Technologies, S.A. | Detection and quantification of siRNA on microarrays |
CA2539651A1 (en) | 2003-09-22 | 2005-04-07 | Rosetta Inpharmatics Llc | Synthetic lethal screen using rna interference |
CN1890382A (zh) * | 2003-09-24 | 2007-01-03 | 肿瘤疗法科学股份有限公司 | 检测、诊断和治疗肝细胞癌(hcc)的方法 |
US20050186589A1 (en) | 2003-11-07 | 2005-08-25 | University Of Massachusetts | Interspersed repetitive element RNAs as substrates, inhibitors and delivery vehicles for RNAi |
US20050164252A1 (en) * | 2003-12-04 | 2005-07-28 | Yeung Wah Hin A. | Methods using non-genic sequences for the detection, modification and treatment of any disease or improvement of functions of a cell |
AU2004305075A1 (en) | 2003-12-19 | 2005-07-07 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies |
EP2295604B1 (en) | 2004-02-09 | 2015-04-08 | Thomas Jefferson University | Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features |
US20050256072A1 (en) | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
AU2005214904B2 (en) | 2004-02-13 | 2011-07-21 | Rockefeller University | Anti-microRNA oligonucleotide molecules |
US7365058B2 (en) | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
KR20070004957A (ko) | 2004-04-20 | 2007-01-09 | 제나코 바이오메디컬 프로덕츠, 인코포레이티드 | ncRNA 검출 방법 |
IL179285A (en) * | 2004-05-14 | 2011-04-28 | Rosetta Genomics Ltd | Micrornas and uses thereof |
EP2471922A1 (en) * | 2004-05-28 | 2012-07-04 | Asuragen, Inc. | Methods and compositions involving microRNA |
US7635563B2 (en) * | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
US20060037088A1 (en) * | 2004-08-13 | 2006-02-16 | Shulin Li | Gene expression levels as predictors of chemoradiation response of cancer |
JP2008511678A (ja) | 2004-09-02 | 2008-04-17 | イェール ユニバーシティ | マイクロrnaによるオンコジーンの調節 |
US7592441B2 (en) | 2004-10-04 | 2009-09-22 | Rosetta Genomics Ltd | Liver cancer-related nucleic acids |
US7642348B2 (en) * | 2004-10-04 | 2010-01-05 | Rosetta Genomics Ltd | Prostate cancer-related nucleic acids |
FR2877350B1 (fr) * | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE |
US8173611B2 (en) * | 2004-11-12 | 2012-05-08 | Asuragen Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
WO2008073922A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Functions and targets of let-7 micro rnas |
EP1824872B1 (en) * | 2004-12-14 | 2012-02-08 | Alnylam Pharmaceuticals Inc. | Rnai modulation of mll-af4 and uses thereof |
US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
EP1959012A3 (en) * | 2004-12-29 | 2009-12-30 | Exiqon A/S | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs |
US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
CA2595716A1 (en) * | 2005-01-25 | 2006-08-03 | Rosetta Inpharmatics Llc | Methods for quantitating small rna molecules |
US20070065840A1 (en) * | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
GB2425311A (en) | 2005-04-15 | 2006-10-25 | Ist Superiore Sanita | Micro RNA against kit protein |
US20070065844A1 (en) * | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
US20060292616A1 (en) | 2005-06-23 | 2006-12-28 | U.S. Genomics, Inc. | Single molecule miRNA-based disease diagnostic methods |
CA2617581A1 (en) | 2005-08-01 | 2007-02-08 | The Ohio State University Research Foundation | Microrna-based methods for the diagnosis of breast cancer |
US20070123482A1 (en) * | 2005-08-10 | 2007-05-31 | Markus Stoffel | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
EP1937280B1 (en) | 2005-09-12 | 2014-08-27 | The Ohio State University Research Foundation | Compositions for the therapy of bcl2-associated cancers |
CA2624531A1 (en) | 2005-10-05 | 2007-04-19 | Carlo M. Croce | Wwox gene, vectors containing the same, and uses in treatment of cancer |
US20070092882A1 (en) * | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
US7390792B2 (en) * | 2005-12-15 | 2008-06-24 | Board Of Regents, The University Of Texas System | MicroRNA1 therapies |
AU2007205257B2 (en) * | 2006-01-05 | 2013-07-25 | The Ohio State University Research Foundation | MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors |
EP2468899B1 (en) | 2006-01-05 | 2015-03-11 | The Ohio State University Research Foundation | MicroRNA-based methods for the diagnosis of stomach cancers |
CN102943108B (zh) | 2006-01-05 | 2014-05-21 | 俄亥俄州立大学研究基金会 | 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物 |
AU2007227423B2 (en) | 2006-03-20 | 2013-11-07 | The Ohio State University Research Foundation | MicroRNA fingerprints during human megakaryocytopoiesis |
US20090324618A1 (en) | 2006-03-24 | 2009-12-31 | Armstrong Scott A | Novel signature self renewal gene expression programs |
WO2007112754A2 (en) | 2006-04-03 | 2007-10-11 | Santaris Pharma A/S | Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides |
JP5127821B2 (ja) * | 2006-04-24 | 2013-01-23 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | miR155トランスジェニックマウスにおけるプレB細胞増殖及びリンパ芽球性白血病/高悪性度リンパ腫 |
EP2369017B8 (en) | 2006-07-13 | 2014-03-12 | The Ohio State University Research Foundation | Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases |
CA2661354C (en) | 2006-08-30 | 2012-12-18 | The Regents Of The University Of Michigan | New small molecule inhibitors of mdm2 and the uses thereof |
US20080193943A1 (en) | 2006-09-05 | 2008-08-14 | Abbott Laboratories | Companion diagnostic assays for cancer therapy |
EP2076599A2 (en) * | 2006-09-19 | 2009-07-08 | Asuragen, Inc. | Mir-200 regulated genes and pathways as targets for therapeutic intervention |
CA2663962A1 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
CN101535505A (zh) * | 2006-09-19 | 2009-09-16 | 俄亥俄州立大学研究基金会 | 慢性淋巴细胞性白血病(CLL)中受miR-29和miR-181调控的TCL1的表达 |
EP2115138A2 (en) * | 2006-09-19 | 2009-11-11 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
WO2008054828A2 (en) * | 2006-11-01 | 2008-05-08 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
US8293684B2 (en) * | 2006-11-29 | 2012-10-23 | Exiqon | Locked nucleic acid reagents for labelling nucleic acids |
WO2008070082A2 (en) * | 2006-12-04 | 2008-06-12 | The Johns Hopkins University | Stem-progenitor cell specific micro-ribonucleic acids and uses thereof |
US20090092974A1 (en) * | 2006-12-08 | 2009-04-09 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
AU2007333107A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-21 regulated genes and pathways as targets for therapeutic intervention |
AU2007333106A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-20 regulated genes and pathways as targets for therapeutic intervention |
CA2671270A1 (en) * | 2006-12-29 | 2008-07-17 | Asuragen, Inc. | Mir-16 regulated genes and pathways as targets for therapeutic intervention |
CN103555825B (zh) * | 2007-01-31 | 2015-09-30 | 俄亥俄州立大学研究基金会 | 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物 |
US8765702B2 (en) * | 2007-02-27 | 2014-07-01 | Rosetta Genomics Ltd. | Composition and methods for modulating cell proliferation and cell death |
WO2008113758A1 (en) * | 2007-03-16 | 2008-09-25 | Covalx Ag | Direct mass spectrometric analysis of drug candidates targeting protein complexes |
TWI367949B (en) | 2007-04-10 | 2012-07-11 | Univ Nat Taiwan | Predicting post-treatment survival in cancer patients with microrn |
EP2610347B1 (en) * | 2007-04-30 | 2015-04-15 | The Ohio State University Research Foundation | Methods of determining the prognosis of a subject with pancreatic cancer |
US20090005336A1 (en) * | 2007-05-08 | 2009-01-01 | Zhiguo Wang | Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions |
US20090232893A1 (en) | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20090131354A1 (en) * | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20090099034A1 (en) * | 2007-06-07 | 2009-04-16 | Wisconsin Alumni Research Foundation | Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers |
JP2010529966A (ja) | 2007-06-08 | 2010-09-02 | アシュラジェン インコーポレイテッド | 治療的介入の標的としてmiR−34によって調節される遺伝子および経路 |
ES2537349T3 (es) | 2007-06-08 | 2015-06-05 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Métodos para determinar un subtipo de carcinoma hepatocelular |
EP2719773A3 (en) * | 2007-06-15 | 2014-07-30 | The Ohio State University Research Foundation | miRNA as marker for acute lamphomic leucemia |
CN103866008B (zh) * | 2007-08-03 | 2016-06-29 | 俄亥俄州立大学研究基金会 | 编码ncrna的超保守区域 |
CA2696887C (en) | 2007-08-22 | 2016-06-28 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
US20090061424A1 (en) * | 2007-08-30 | 2009-03-05 | Sigma-Aldrich Company | Universal ligation array for analyzing gene expression or genomic variations |
EP2775001B1 (en) | 2007-09-06 | 2016-03-09 | The Ohio State University Research Foundation | MicroRNA signatures in human ovarian cancer |
US20090123933A1 (en) * | 2007-11-12 | 2009-05-14 | Wake Forest University Health Sciences | Microrna biomarkers in lupus |
WO2009070805A2 (en) * | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
WO2009086156A2 (en) * | 2007-12-21 | 2009-07-09 | Asuragen, Inc. | Mir-10 regulated genes and pathways as targets for therapeutic intervention |
CN102084000B (zh) | 2008-02-01 | 2016-03-16 | 总医院有限公司 | 微泡在医学疾病和病况的诊断、预后以及治疗中的用途 |
US20090263803A1 (en) | 2008-02-08 | 2009-10-22 | Sylvie Beaudenon | Mirnas differentially expressed in lymph nodes from cancer patients |
WO2009111643A2 (en) | 2008-03-06 | 2009-09-11 | Asuragen, Inc. | Microrna markers for recurrence of colorectal cancer |
US20090253780A1 (en) | 2008-03-26 | 2009-10-08 | Fumitaka Takeshita | COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER |
WO2009137807A2 (en) | 2008-05-08 | 2009-11-12 | Asuragen, Inc. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
WO2009149418A2 (en) | 2008-06-06 | 2009-12-10 | Asuragen, Inc. | Novel compositions for the in vivo delivery of rnai agents |
-
2006
- 2006-09-11 EP EP06814375.9A patent/EP1937280B1/en not_active Not-in-force
- 2006-09-11 ES ES06814375.9T patent/ES2523989T3/es active Active
- 2006-09-11 CN CN2006800397768A patent/CN101296702B/zh not_active Expired - Fee Related
- 2006-09-11 EP EP14178114.6A patent/EP2796554A3/en not_active Withdrawn
- 2006-09-11 CA CA2621441A patent/CA2621441C/en not_active Expired - Fee Related
- 2006-09-11 JP JP2008531200A patent/JP2009507918A/ja active Pending
- 2006-09-11 CN CN201210380806.9A patent/CN103028120B/zh not_active Expired - Fee Related
- 2006-09-11 WO PCT/US2006/035100 patent/WO2007033023A2/en active Application Filing
- 2006-09-11 CA CA2845251A patent/CA2845251A1/en not_active Abandoned
- 2006-09-11 US US11/991,773 patent/US8481505B2/en not_active Expired - Fee Related
- 2006-09-11 AU AU2006291165A patent/AU2006291165B2/en not_active Ceased
-
2013
- 2013-04-10 JP JP2013081761A patent/JP2013166766A/ja active Pending
- 2013-06-14 US US13/918,087 patent/US20130267580A1/en not_active Abandoned
-
2014
- 2014-07-25 US US14/341,145 patent/US9480699B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009507918A5 (ja) | ||
US11452750B2 (en) | Oncolytic viral vectors and uses thereof | |
US20230241140A1 (en) | Oncolytic viral vectors and uses thereof | |
Xie et al. | MicroRNAs as regulators, biomarkers and therapeutic targets in the drug resistance of colorectal cancer | |
Banelli et al. | MicroRNA in glioblastoma: an overview | |
Amodio et al. | miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies | |
ES2429404T3 (es) | Procedimientos basados en los microARN para el diagnóstico y el pronóstico del cáncer de pulmón | |
JP5837909B2 (ja) | 固形癌の診断及び治療のためのマイクロrnaに基づく方法及び組成物 | |
ES2446362T3 (es) | Huellas de microARN durante megacariocipoyesis humana | |
ES2524018T3 (es) | Anomalías de la expresión de microARN en tumores pancreáticos endocrinos y acinares | |
JP2009529916A5 (ja) | ||
CN101296702A (zh) | 用于诊断或治疗bcl2相关癌症的组合物和方法 | |
Ghafouri-Fard et al. | Expression of non-coding RNAs in hematological malignancies | |
Cortez et al. | microRNAs in cancer: from bench to bedside | |
da Silva et al. | miRNAs mediated drug resistance in hematological malignancies | |
Mirzaei et al. | Exosomes and microRNAs in biomedical science | |
AU2016203583A1 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers | |
CN115461461A (zh) | 用于促进免疫原性细胞死亡的miRNA-193a | |
Milani | Emerging strategies for selective targeting in therapeutic approaches against gliomas | |
Cohena et al. | Supplementary Material microRNAs Downregulation in Cancer is Associated with Guanine Enrichment in the Terminal Loop Sequences of their Precursors |